Several type I/III IFN, NF-kB and TLR pathways-related UR molecules, predicted to be activated by guadecitabine in-vitro in melanoma cell lines, were also predicted to be activated in-vivo by this DNMT inhibitor (Suppl. Here, NFKB1 is linked to melanoma.